Active, not recruitingPhase 3NCT03703375

Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

Studying Angioimmunoblastic T-cell lymphoma

Last synced from ClinicalTrials.gov May 4, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Celgene
Principal Investigator: Bristol-Myers Squibb
Bristol-Myers Squibb
Intervention: Azacitidine(drug)
Enrollment: 93 enrolled
Eligibility: 18 years · All sexes
Timeline: 2018 – 2026

Study locations (12)

Local Institution - 41822, Sapporo, Hokkaido, Japan
Local Institution - 41922, Okayama, Okayama-ken, Japan
Local Institution - 41722, Sayama, Osaka, Japan
Local Institution - 41422, Hidaka, Saitama-Pref, Japan
Local Institution - 40722, Chuo-ku, Tokyo, Japan
Local Institution - 40222, Koto-ku, Tokyo, Japan
Local Institution - 40922, Fukuoka, Japan
Local Institution - 40122, Isehara City, Kanagawa, Japan
Local Institution - 41522, Kashiwa, Japan
Local Institution - 41622, Nagoya, Japan
Local Institution - 41222, Sendai, Japan
Local Institution - 41322, Tsukuba, Japan

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03703375 on ClinicalTrials.gov

Other trials for Angioimmunoblastic T-cell lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Angioimmunoblastic T-cell lymphoma →

← Back to all trials